BTAI
BioXcel Therapeutics IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$28.70M
P/E Ratio
—
EPS
$-5.73
Beta
0.30
52W High
$8.08
52W Low
$1.01
50-Day MA
$1.38
200-Day MA
$2.20
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.
Fundamentals
| Revenue (TTM) | 642,000 |
| Gross Profit (TTM) | 478,000 |
| EBITDA | $-49.97M |
| Operating Margin | -4016.00% |
| Return on Equity | -1767.00% |
| Return on Assets | -75.50% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $-4.28 |
| Price-to-Book | 27.50 |
| Price-to-Sales (TTM) | 44.70 |
| EV/Revenue | 172.52 |
| EV/EBITDA | -0.76 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -30.10% |
| Shares Outstanding | $27.07M |
| Float | $24.67M |
| % Insiders | 3.84% |
| % Institutions | 15.37% |
Historical Volatility
HV 10-Day
63.58%
HV 20-Day
61.12%
HV 30-Day
67.00%
HV 60-Day
81.71%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($14.00 target)
3
Buy1
Strong SellData last updated: 4/29/2026